Arrowhead Pharmaceuticals begins phase-1/2a study with ARO-ALK7 for the treatment of obesity
Breaking News: Arrowhead Pharmaceuticals Launches Phase 1/2a Study for Obesity Treatment In a groundbreaking development, Arrowhead Pharmaceutical, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, … Read More